This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish: Clotting factor levels and COVID-19 General field: Medical Detailed field: Medical (general)
Source text - English Patients who are hospitalized with severe COVID-19 infections and have high levels of the blood-clotting protein factor V are at elevated risk for serious injury from blood clots such as deep vein thrombosis or pulmonary embolism, according to HMS investigators at Massachusetts General Hospital. In addition, patients who are critically ill with COVID-19 and have low levels of factor V appear to be at increased risk for death from a coagulopathy that resembles disseminated intravascular coagulation (DIC), a devastating, often fatal, abnormality in which blood clots form in small vessels throughout the body, leading to an exhaustion of the clotting factors and proteins that control coagulation.
The findings, based on studies of patients with COVID-19 in Mass General intensive care units, indicate that disturbances in factor V activity can be used to identify at-risk patients with the goal of selecting the proper anticoagulation therapy.
In March 2020, the researchers noted that a blood sample from a ventilated patient with COVID-19 contained factor V levels well above the normal reference range. The patient later developed a saddle pulmonary embolism, a potentially fatal blood clot occurring at the junction of the left and right pulmonary arteries.
This observation led investigators to look at the activity of factor V as well as factor VIII and factor X, two other major clotting factors. They studied the levels of these clotting factors and other parameters in 102 consecutive patients with COVID-19 and compared the results with those in contemporaneous critically ill patients without COVID-19, and in historical controls.
They found that, compared with controls, factor V levels were significantly higher among patients with COVID-19 and that the association between high factor V activity and COVID-19 was the strongest among all clinical parameters studied.
In all, 33 percent of patients with factor V activity well above the reference range had either deep vein thrombosis or a pulmonary embolism, compared with only 13 percent of patients with lower levels. Death rates were significantly higher for patients with lower levels of factor V (30 percent vs. 12 percent), with evidence indicating this was due to progression to a DIC-like state.
Translation - Spanish Los pacientes hospitalizados gravemente infectados de COVID-19 y con niveles elevados de la proteína de coagulación sanguínea factor V están en alto riesgo de heridas graves causadas por coágulos sanguíneos, como la trombosis venosa profunda o la embolia pulmonar, de acuerdo con los investigadores de la Escuela de Medicina Harvard en el Hospital General de Massachussets. Además, los pacientes críticamente enfermos de COVID-19 con niveles bajos de factor V parecen estar expuestos a un mayor riesgo de muerte por una coagulopatía similar a la coagulación intravascular diseminada (CID), una anomalía devastadora y con frecuencia letal en la cual se forman coágulos sanguíneos en pequeñas vesículas por todo el cuerpo, causando el agotamiento de los factores coagulantes y de las proteínas que controlan la coagulación.
Estos hallazgos, basados en estudios de pacientes con COVID-19 en unidades de cuidados intensivos del Hospital General de Massachussets, indican que las interrupciones en la actividad del factor V pueden usarse para identificar pacientes en riesgo con el objetivo de seleccionar una terapia anticoagulante apropiada.
En marzo del 2020, los investigadores notaron que una muestra de sangre de un paciente con ventilación enfermo de COVID-19 contenía niveles del factor V mucho más altos que el intervalo normal de referencia. El paciente desarrolló luego embolia pulmonar «en silla de montar», un coágulo sanguíneo potencialmente letal en el cruce de las arterias pulmonares izquierda y derecha.
Esta observación llevó a los investigadores a examinar la actividad del factor V, así como del factor VIII y el factor X, otros dos factores coagulantes principales. Se estudiaron los niveles de dichos factores coagulantes y otros parámetros en 102 pacientes con COVID-19 consecutivos, y se compararon los resultados con los de pacientes contemporáneos críticamente enfermos sin COVID-19, y con controles históricos.
Se encontró que, en comparación con los controles, los niveles del factor V eran significativamente más altos entre los pacientes con COVID-19, y que la asociación entre una alta actividad del factor V y el COVID-19 era la mayor entre todos los parámetros estudiados.
En conclusión, el 33 % de los pacientes cuya actividad del factor V era mucho mayor que el intervalo de referencia tenía trombosis venosa profunda o embolia pulmonar, en comparación con solo el 13 % de los pacientes con niveles más bajos. La tasa de mortalidad era significativamente más alta en los pacientes con niveles más bajos del factor V (30 % contra 12 %), y la evidencia indicó que eso se debía a la progresión hacia un estado similar a la CID.
More
Less
New! Video portfolio:
More
Less
Translation education
Graduate diploma - Universidad Nacional de Córdoba
Experience
Years of experience: 3. Registered at ProZ.com: Mar 2021.
I discovered my love for the English language after getting into the wrong course of study. I decided then to become an English<>Spanish translator. At the Universidad Nacional de Córdoba (National University of Córdoba) I was one of the few students who graduated after only five years.
I have always liked literature, and therefore, literary translation. But I also developed a love for subtitling and how practical and useful it is. I have taken several online courses, such as subtitling courses and a Trados Studio course, to improve my professional skills.
I realized that I needed to specialize to move forward in my career, so I chose to specialize in healthcare and medical translation. Today, audiovisual translation is my favorite field, but I also hope to specialize in literary and culinary translation in the future.
Keywords: english, spanish, english to spanish, spanish to english, subtitler, subtitling, translator, translating, healthcare, medical translation. See more.english, spanish, english to spanish, spanish to english, subtitler, subtitling, translator, translating, healthcare, medical translation, healthcare translation, literary translation, literature, mtpe, proofreading. See less.
Expertise